Marker Therapeutics, Inc.

News

TapImmune To Present at 2018 Janney Healthcare Conference

Peter L. Hoang will be presenting at the 2018 Janney Healthcare Conference.
Read More

Baylor, MD Anderson Cancer Therapies Advance Toward Commercialization

Recently, two TMC member institutions saw their cancer therapies gain the distinction of advancing to commercialization.
Read More

TapImmune to Participate at Two Upcoming Industry Conferences

Peter L. Hoang will be participating in two industry conferences next week.
Read More

Companies Merge to Implement Baylor College of Medicine-Developed Therapies for Cancer

The researchers developed a novel therapy for cancer patients that harnesses the patient’s own immune system to fight cancer in a natural way. This therapy uses a ‘natural’ T cell response that does not require genetic engineering.
Read More

New Details Emerge on TapImmune Merger

TapImmune Inc., Jacksonville's publicly traded developer of cancer-fighting immunotherapies, announced in May that it was merging with Minnesota-based Marker Therapeutics Inc., another developer of immunotherapies.
Read More

No Revenue, but TapImmune Leads Pack

Company developing immunotherapy treatments for cancer up 139 percent this year.
Read More

This Jacksonville Company’s Stock is Surging as the Market sees there’s “No Competitor”

TapImmune Inc. stock has blossomed in the month since it announced it will merge with a company producing similar cancer-fighting treatments, begin a strategic alliance with Baylor College of Medicine and move to Houston. The stock has more than tripled since the announcement and rose more than 18 percent Friday.
Read More

TapImmune Announces Pricing of $70 Million Private Placement

TapImmune today announced that it has entered into security purchase agreements with certain institutional and accredited investors in connection with a private placement of its equity securities. The private placement will be led by New Enterprise Associates (NEA) with participation from Aisling Capital and Perceptive Advisors, among other new and existing investors.
Read More

TapImmune Poised To Become A Cell Therapy Leader, WBB Securities Says In Upgrade

TapImmune will pursue a new approach to treating cancer through a proposed merger with privately held Marker Therapeutics, a WBB Securities analyst said in an upgrade note.
Read More

The Kite Killer – TapImmune And Marker Merger Challenges Gilead

History could be repeating itself and TapImmune (NASDAQ:TPIV) could be Kite 2.0.
Read More